Compare FET & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | DRUG |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.5M | 707.1M |
| IPO Year | 2007 | 2020 |
| Metric | FET | DRUG |
|---|---|---|
| Price | $53.64 | $74.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $129.25 |
| AVG Volume (30 Days) | 124.3K | ★ 255.8K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.64 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $791,474,000.00 | N/A |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $133.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $23.18 |
| 52 Week High | $65.43 | $123.75 |
| Indicator | FET | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 37.08 |
| Support Level | $48.86 | $70.35 |
| Resistance Level | $63.59 | $77.01 |
| Average True Range (ATR) | 2.65 | 5.15 |
| MACD | -0.28 | -1.01 |
| Stochastic Oscillator | 45.66 | 8.31 |
Forum Energy Technologies Inc is a manufacturing company serving the oil, natural gas, industrial, and renewable energy industries. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. The company operates in two reportable segments: Drilling and Completions, and Artificial Lift and Downhole. Maximum revenue is generated from the Drilling and Completions segment, which offers products used in the drilling process, and other products like hydraulic fracturing pumps, ROVs and trenchers, submarine rescue vehicles, etc. Geographically, the firm generates maximum revenue from the U.S., followed by Canada, Middle East, Europe and Africa, Asia-Pacific, and Latin America.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.